Real-world experience of palbociclib and ribociclib: novel oral therapy in metastatic breast cancer.

Background Palbociclib and ribociclib are novel oral agents in hormone receptor-positive metastatic breast cancer. Neutropenia is a common adverse event associated with these treatments and its clinical management often requires regimen changes, such as cycle delays and dose adjustments. Objective To provide a real-world experience of the effectiveness and toxicities associated with these drugs and to evaluate the impact of regimen changes in disease progression. Setting This study was performed at Hospital Universitario La Paz, in Spain. Methods Observational, retrospective study which included hormone receptor-positive metastatic breast cancer patients who initiated treatment with palbociclib or ribociclib between March 1st, 2018 and March 1st, 2019. Main outcome measure The primary effectiveness variable was progression-free survival. Safety evaluation was performed to determine neutropenia-incidence and severity, as well as its clinical management, including dose adjustments and treatment interruptions. Correlations between these regimen changes and effectiveness were also evaluated. Results Sixty-one patients were included, 33 treated with palbociclib and 28 with ribociclib. Palbociclib was mainly used as second line of treatment in the metastatic setting (81.8%) and ribociclib as first line (67.9%). The median progression-free survival was 12.76 months (95% CI 7.5 to not estimable) in palbociclib and not reached in ribociclib. After 12 months, the progression-free survival rate was 51.5% (95% CI 34-69) in palbociclib and 78.6% (95% CI 63-94.1) in ribociclib. Neutropenia was the most common adverse event with an incidence rate of 87.9% in palbociclib and 82.1% in ribociclib. Cycle delays were needed in more than half of the patients treated with palbociclib and ribociclib (63.6% and 64.3%). Dose adjustments were seen in 42.4% and 53.6% of the patients receiving palbociclib and ribociclib, respectively. Regimen changes did not involve statistically significant differences in 12-month PFS rates in the cohort investigated. Conclusion Palbociclib and ribociclib outcomes are comparable to those reached in the phase III trials, PALOMA-3 and MONALEESA-2, respectively, and cannot be compared as they were used in different treatment settings. The toxicity profile is favourable, being neutropenia the most common adverse event, easily managed with regimen changes. Further studies are needed to confirm the observed tendency of no detrimental impact on effectiveness of these regimen changes.

Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience.

INTRODUCTION: The aim of this study is to evaluate the cost-effectiveness and impact of gene-expression assays (GEAs) on treatment decisions in a real-world setting of early-stage breast cancer (ESBC) patients. METHODS: This is a regional, prospective study promoted by the Council Health Authorities in Madrid. Enrolment was offered to women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, node-negative or micrometastatic, stage I or II breast cancer from 21 hospitals in Madrid. Treatment recommendations were recorded before and after knowledge of tests results. An economic model compared the cost-effectiveness of treatment, guided by GEAs or by common prognostic factors. RESULTS: 907 tests (440 Oncotype DX® and 467 MammaPrint®) were performed between February 2012 and November 2014. Treatment recommendation changed in 42.6% of patients. The shift was predominantly from chemohormonal (CHT) to hormonal therapy (HT) alone, in 30.5% of patients. GEAs increased patients' confidence in treatment decision making. Tumor grade, progesterone receptor positivity and Ki67 expression were associated with the likelihood of change from CHT to HT (P < 0.001) and from HT to CHT (P < 0.001). Compared with current clinical practice genomic testing increased quality-adjusted life years by 0.00787 per patient and was cost-saving from a national health care system (by 13.867€ per patient) and from a societal perspective (by 32.678€ per patient). CONCLUSION: Using GEAs to guide adjuvant therapy in ESBC is cost-effective in Spain and has a significant impact on treatment decisions.

Evaluación de la eficacia de un suplemento oral en polvo enriquecido con ácido eicosapentaenoico en un grupo de pacientes con cáncer / Efficacy evaluation of an oral powder supplement enriched with eicosapentaenoic acid in cancer patients

Introducción: El efecto beneficioso del ácido eicosapentaenoico en pacientes con cáncer está ampliamente descrito sobre todo en lo que respecta a su rol en la caquexia tumoral. Objetivo: Evaluar la eficacia de la administración de un nuevo suplemento oral en polvo con adición de este componente frente a un suplemento líquido estándar en un grupo de pacientes oncológicos. Pacientes y métodos: 61 adultos mayores de 18 años de ambos sexos con cáncer, fueron aleatorizados en dos grupos para recibir durante un mes 600 kcal extras añadidas a su alimentación; uno a través de un suplemento oral en polvo con 1,5 g de ácido eicosapentaenoico/día (RSI) y el otro con un producto líquido estándar (RE). Tanto al inicio como al final del estudio se realizaron las siguientes medidas: valoración global subjetiva generada por el paciente (VGS-gp), parámetros antropométricos (Pliegues, circunferencia del brazo y bioimpedancia), dietéticos (registro alimentario de 72 horas), bioquímicos e inflamatorios (bioquímica básica, citoquinas, prealbúmina y PCR). La calidad de vida fue valorada mediante el cuestionario SF-36. Así mismo se emplearon escalas de percepción sensorial, tolerancia de los productos y motivación y saciedad al comer durante el estudio. Resultados: Finalizaron el estudio 40 pacientes. Tras la intervención ambos grupos mantuvieron sus parámetros antropométricos y aumentaron significativamente la prealbúmina (RSI 16,11 ± 5,66 mg/dl vs 19.81 ± 6.75 mg/dl p < 0,05 y RE 16.55 ± 6.13 mg/dl vs 19.03 ± 5.47 mg/dl p < 0,05). El grupo RSI disminuyó significativamente los valores de interferón gamma (INF-γ) (0,99 ± 0,95 vs 0,65 ± 0,92 pg/ml, p < 0,05). Sin embargo, el grupo RE los aumentó al final del estudio (1,62 ± 1,27 vs 2,2 ± 3,19 pg/ml, p < 0,05). No se encontraron diferencias significativas en la sensación de hambre, apetito, saciedad y capacidad de ingesta tras la intervención en ambos grupos. Las puntuaciones del SF-36 mejoraron en ambos grupos. Conclusión: La suplementación durante un mes de un producto en polvo enriquecido con 1,5 g de EPA en una población de pacientes con cáncer, modula positivamente ciertos parámetros inflamatorios. Este producto podría ser una opción nueva a tener en cuenta que podría sumarse a las estrategias de intervención para el tratamiento nutricional del paciente oncológico (AU)

Background and objectives: The beneficial effect of eicosapentaenoic acid in cancer patients is widely described especially in relation to its role in tumour cachexia. The aim of the study was to evaluate the efficacy of administration of a new oral powder supplement enriched with eicosapentaenoic acid compared to a standard liquid supplement in cancer patients. Patients and methods: A total of 61 cancer patients, aged more than 18 years, were randomized to receive during a month a bonus of 600 kcal/ day to their regular diet with an oral powder supplement enriched with eicosapentaenoic acid (1.5 g) (RSI) or with a standard liquid supplement (RE). The following data were collected at baseline and after one month: the Patient-Generated Subjective Global Assessment (pg-SGA), anthropometric measurements (skin folds, circumferences and bioimpedance), dietary parameters (3-day food record), biochemical and inflammatory parameters (basic biochemistry, cytokines, prealbumin and Reactive C Protein). Quality of life was evaluated using the SF-36 questionnaire. At the end, scales were used to asses sensory perception, tolerance and satiety induced by the products and motivation to eat. Results: 40 patients completed the study. After intervention, anthropometric parameters do not change and prealbumin values increased significantly in both groups (RSI 16.11 ± 5.66 mg/dl vs. 19.81 ± 6.75 mg/dl p < 0.05 and RE 6.13 ± 16.55 mg/dl vs. 19.03 ± 5.47 mg / dl p < 0.05). RSI group significantly decreased interferon gamma (INF-γ) values (0.99 ± 0.95 vs. 0.65 ± 0.92 pg/ml, p < 0.05). In contrast, RE group increased INF-γ after intervention (1.62 ± 1 27 vs. 2.2 ± 3.19 pg/ml, p < 0.05). There were no significant differences in hunger, appetite, satiety and intake capacity in both groups. The SF-36 scores improved in both groups. Conclusions: Supplementation based on an oral powder formula enriched with 1.5g EPA during one month in cancer patients improved certain inflammatory parameters. This product may be a novel and valuable option to be added to the nutritional intervention strategies used for cancer patients (AU)

Adjuvant hormonal therapy in perimenopausal patients.

This section considers the treatment options for perimenopausal women with breast cancer. The perimenopause period begins in the so-called stage 2 of menopausal transition (early menopausal transition, where the length of the cycles changes by 7 days or more) and ends after 12 months of amenorrhea. It is characterized by an early increase in follicle-stimulating hormone and is associated with the presence of anovulatory cycles, irregular periods, and loss of menstrual cycles. The recommended treatment is tamoxifen (TAM) with or without ovarian ablation for 2 or 3 years followed by a re-evaluation. TAM should be maintained if the patient is premenopausal and aromatase inhibitors (AI) are recommended once the menopausal status is confirmed. Ovarian suppression is an acceptable adjuvant therapy in those patients with hormone-sensitive tumors. AI should only be used in postmenopausal women or in combination with chemical castration in premenopausal women. This supplement paper includes the key points of roundtable presentations and discussions of hormonal therapy in breast cancer.

[Efficacy evaluation of an oral powder supplement enriched with eicosapentaenoic acid in cancer patients]. / Evaluación de la eficacia de un suplemento oral en polvo enriquecido con ácido eicosapentaenoico en un grupo de pacientes con cáncer.

BACKGROUND AND OBJECTIVES: The beneficial effect of eicosapentaenoic acid in cancer patients is widely described especially in relation to its role in tumour cachexia. The aim of the study was to evaluate the efficacy of administration of a new oral powder supplement enriched with eicosapentaenoic acid compared to a standard liquid supplement in cancer patients. PATIENTS AND METHODS: A total of 61 cancer patients, aged more than 18 years, were randomized to receive during a month a bonus of 600 kcal/ day to their regular diet with an oral powder supplement enriched with eicosapentaenoic acid (1.5 g) (RSI) or with a standard liquid supplement (RE). The following data were collected at baseline and after one month: the Patient-Generated Subjective Global Assessment (pg-SGA), anthropometric measurements (skin folds, circumferences and bioimpedance), dietary parameters (3-day food record), biochemical and inflammatory parameters (basic biochemistry, cytokines, prealbumin and Reactive C Protein). Quality of life was evaluated using the SF-36 questionnaire. At the end, scales were used to asses sensory perception, tolerance and satiety induced by the products and motivation to eat. RESULTS: 40 patients completed the study. After intervention, anthropometric parameters do not change and prealbumin values increased significantly in both groups (RSI 16.11 ± 5.66 mg/dl vs. 19.81 ± 6.75 mg/dl p < 0.05 and RE 6.13 ± 16.55 mg/dl vs. 19.03 ± 5.47 mg / dl p < 0.05). RSI group significantly decreased interferon gamma (INF-γ) values (0.99 ± 0.95 vs. 0.65 ± 0.92 pg/ml, p < 0.05). In contrast, RE group increased INF-γ after intervention (1.62 ± 1 27 vs. 2.2 ± 3.19 pg/ml, p < 0.05). There were no significant differences in hunger, appetite, satiety and intake capacity in both groups. The SF-36 scores improved in both groups. CONCLUSIONS: Supplementation based on an oral powder formula enriched with 1.5 g EPA during one month in cancer patients improved certain inflammatory parameters. This product may be a novel and valuable option to be added to the nutritional intervention strategies used for cancer patients.

Intra-abdominal desmoplastic small round cell tumour in a 39-year-old man

Desmoplastic small round cell tumor is a very rare neoplasm, that usually appears in children and young adolescents. There is no standard therapy, and responses to chemotherapy are infrequent. Surgery is still the main treatment for this disease. We report the case of a 39 year-old man and briefly summarize the evidence about this tumor (AU)

No disponible

Evaluación del riesgo nutricional e instauración de soporte nutricional en pacientes oncológicos, según el protocolo del grupo español de Nutrición y Cáncer / Nutricional risk evaluation and establishment of nutricional support in oncology patients according to the protocol of the spanish nutrition and cancer group

Introducción: El cáncer, los tratamientos que lo acompañan y los síntomas consecuentes que a su vez generan, aumentan en los pacientes el riesgo de sufrir malnutrición. La cual produce un gran deterioro del estado de salud, con el consecuente aumento de complicaciones, disminución de la tolerancia al tratamiento oncológico y una disminución de la calidad de vida del paciente. Por este motivo, un grupo de profesionales sanitarios de diferentes puntos de España se reunieron con el objetivo de mejorar la intervención nutricional en pacientes oncológicos, con el apoyo de la Sociedad Española de Nutrición Básica y Aplicada (SENBA). Metodología: Este grupo multidisciplinar de profesionales elaboró un documento de consenso basado en la literatura y en la experiencia personal, creando un protocolo de evaluación y de intervención nutricional en forma de algoritmos. Se clasifican los pacientes en tres pasos: 1. según el tipo de tratamiento oncológico que reciben, ya sea de tipo curativo o paliativo; 2. riesgo nutricional de la terapia antineoplásica (bajo, mediano, o alto riesgo), y 3. de acuerdo a la Valoración Global Subjetiva-Generada por el paciente (VGS-gp), que clasifica a los pacientes en: A. pacientes con adecuado estado nutricional, B. pacientes con malnutrición o a riesgo de malnutrición y C. pacientes con malnutrición severa. Durante un año el protocolo se puso en marcha en 226 pacientes mayores de 18 años de ambos sexos, escogidos al azar en las consultas externas de Radioterapia Oncológica y Oncología Médica. Resultados: Más de la mitad sufren malnutrición (64%), y este valor se incrementa llegando hasta un 81% en pacientes con tratamiento paliativo. La mayoría de los pacientes tienen tratamiento de intención curativa (83%) y reciben tratamiento oncológico de intensidad moderada o de alto riesgo nutricional (69%). Un 68% de los pacientes tienen algún tipo de dificultad en la alimentación. La media en el porcentaje de pérdida de peso es del 6,64% ± 0,87 (min 0, máx 33%). El 32% de la población presenta cifras de albúmina entre 3 y 3,5 g/dl, existiendo una correlación negativa entre ésta y las dificultades con la alimentación p = 0,001. El IMC no mostró ser un parámetro significativo para detectar malnutrición (sólo un 10% se encontraba por debajo de 19,9 kg/m2), pero tiene una tendencia lineal significativa con las dificultades en la alimentación, de forma tal que a medida que disminuye el IMC aumentan las dificultades p = 0,001. Más de la mitad de la población, requirió recomendaciones dietéticas específicas para el control de los síntomas que dificultaban la ingesta y una tercera parte de la población necesitó la indicación de suplementos nutricionales. Tras la intervención nutricional más de la mitad (60%) mantuvo su peso y una sexta parte lo aumentó. Conclusión: La aplicación de este protocolo es útil, sencillo y podría facilitar la detección de malnutrición en los pacientes oncológicos. Seleccionando a los pacientes que realmente se podrían beneficiar de una intervención nutricional específica, pero debería aplicarse al inicio coincidiendo si fuera posible con el diagnóstico de la enfermedad. El soporte nutricional resulta eficaz en la mayoría de los pacientes (AU)

Introduction: Cancer and its oncological treatment cause symptoms which increase the patients risk to suffer from malnutrition. This affects the patients health status negatively by increasing the number of complications, reducing the tolerance to the oncology treatment and a decrease of the patients quality of life. Motivated by this, a group of health professionals from several spanish regions met with the backing of the Sociedad Española de Nutrición Básica y Aplicada (SENBA) to address strategies to improve the quality of nutritional intervention in cancer patients. Methods: This multidisciplinary group developed a protocol describing nutritional assessment and intervention in form of algorithms based on literature and personal experience. The patients are classified in a three step process: 1. type of their oncology treatment (curative or palliative); 2. nutritional risk of the antineoplastic therapy (low, medium or high risk) and 3. depending on the Subjective Global Assessment patient-generated (SGApg). The patients are classified as: A. patients with adequate nutritional state, B. patients with malnutrition or risk of malnutrition and C. patients suffering from severe malnutrition. During one year, the protocol has been used for 226 randomly chosen female and male patients older than 18 years. They were treated by the Medical and Radiotherapy Oncology outpatient clinic. Results: More than a half of the patients were suffering from malnutrition (64%) increasing up to 81% for patients undergoing palliative treatment. Most of them were treated curatively (83%) and received oncology treatment with moderate or high nutritional risk (69%). 68% of patients were affected by some feeding difficulty. The mean percentage of weight loss has been 6.64% ± 0.87 (min 0%, max 33%). Albumin values of 32% of the patients were between 3 and 3.5 g/dl and negatively correlated with feeding difficulties (p = 0.001). The body mass index (BMI) has not found to be a significant parameter for detecting malnutrition (only in 10% of the patients, the value was below 19.9 kg/m2). But a significant linear tendency when compared to feeding problems could be shown, such that in patients with less feeding problems a higher BMI has been found (p = 0.001). More than a half of the patients required nutritional counselling to control symptoms which made food intake difficult. One third of the patients needed oral nutritional supplementation. Following the nutritional intervention the weight of about 60% of the patients could be maintained and of one sixth it could be increased. Conclusion: The application of this protocol is useful, easy and could help detecting malnutrition in oncology patients. It provides the possibility to select those patients who can benefit from a specific nutritional intervention. If possible, the application of the protocol should be started immediatly after cancer is diagnosed. Nutritional support proves efficient for most of the patients (AU)

Autopercepción de los pacientes con cáncer sobre la relación existente entre su estado nutricional, su alimentación y la enfermedad que padecen / Self-perception of cancer patients on the relationship existing between their nutritional status, their feeding status, and their illness

Introducción: Conocer la opinión de los pacientes oncológicos sobre la importancia que dan a su alimentación, a las dificultades para alimentarse, su imagen, su peso, los cambios ponderales, la relación entre su alimentación y su enfermedad, la relación entre la actividad física y el estado de ánimo y su salud, es básico para buscar alternativas terapéuticas nutricionales que nos lleven a mejorar su calidad de vida y en general su sensación de bienestar. Para ello, es imprescindible conocer la opinión de los pacientes respecto a estos temas. Material y métodos: Se elaboró una encuesta a 131 pacientes. Los pacientes fueron reclutados en el Hospital de día de Oncología Médica, consulta de Oncología Radioterápica y el Servicio de Hospitalización de Oncología Médica. En la encuesta se preguntó de manera sencilla sobre la importancia que dan los pacientes a todos estos aspectos. Ha sido una encuesta de 20 preguntas, dividida en 6 partes: 1) Datos de filiación. 2) Percepción de la enfermedad y la relación de ésta con la alimentación. 3) Percepción de la relación de la actividad física y del estado de ánimo con la alimentación. 4) Tratamientos nutricionales indicados al paciente y la percepción de su efecto sobre la evolución de la enfermedad. 5) Dificultades actuales de alimentación. 6) Demanda de atención nutricional. Resultados: Los pacientes presentaban una edad media de 57 ± 13 años. El 45% correspondían a hombres y el resto mujeres. El 81% vive en el área urbana, y solo el 14% en el área rural. El nivel educativo se clasificó en 5 grupos: sin estudios, estudios básicos, EGB, bachiller superior o estudios universitarios. El 28% poseía estudios básicos, el 19% estudios universitarios, y un 8% no tenía ningún estudio. Con respecto a su ocupación también se clasificó en cinco grupos: hogar, estudiante, sin empleo, empleado y jubilado. Un 33% eran empleados, 29% jubilados y un 34% se ocupaba del hogar. La mayoría de los pacientes , un 74% son conscientes de su enfermedad y la perciben como grave o muy grave. La mayoría de estos pacientes están pendientes de su imagen, de su peso y de los cambios ponderales y los relacionan con su alimentación. El 74% de los pacientes encuentran relación entre su estado nutricional y la actividad física que desarrollan y un 73% lo relacionan con su estado de ánimo. Al menos la mitad de los pacientes perciben su estado de ánimo como decaído. Aunque el 47% manifiesta tener alguna dificultad para alimentarse, sólo el 34% ha recibido alguna información sobre su alimentación, el 26% ha consumido suplementos nutricionales y el 81% continúa consumiendo una dieta sin modificaciones. Las dificultades de alimentación más comunes fueron disminución del apetito 38%, saciedad precoz 32% y náuseas 20%. La intervención nutricional más solicitada por los pacientes es la educación nutricional general y específica para paliar los síntomas asociados a los tratamientos oncológicos. Conclusiones: La mayoría de los pacientes son consientes de la gravedad de su enfermedad y están pendientes de su imagen, peso y cambios ponderales, que asocian con su alimentación. La mayoría de los pacientes encontraron una estrecha asociación entre su estado nutricional, la actividad física que desarrollan y su estado de ánimo. Más de la mitad manifestó tener alguna dificultad para alimentarse pero sólo a un tercio de la población se le había hablado de su alimentación en alguna ocasión. Es evidente que el paciente oncológico necesita de diferentes medidas de intervención nutricional efectivas que contribuyan a mejorar su sensación de bienestar (AU)

Introduction: Knowing the opinion of oncologic patients about the importance they give to their feeding, the difficulties they have with feeding, their body image, weight, and ponderal changes, the relationship between their feeding and their illness, the relationship between their physical activity and their mood and health is essential to look for nutritional therapeutic interventions leading to improvement of quality of life and, in general, the feeling of well being. Thus, it is paramount to know the patients' opinion of these issues. Material and methods: We passed a questionnaire to 131 patients. The patients were recruited from the Day-Hospital of the Medical Oncology and Radiotherapeutic Oncology Departments, and from the Hospitalization Department of Medical Oncology. In the questionnaire, we asked in a simple manner about the importance the patients give to all these issues. This is a 20-item questionnaire, divided into six parts: 1. Vital statistics; 2) perception about the disease and its relationship with feeding; 3) Perception of the relationship between physical activity and mood with feeding; 4) Nutritional therapies prescribed to the patients and their perception on its effect on the disease progression; 5) Current difficulties with feeding; 6) Demand of nutritional care. Results: The patients mean age was 57 ± 13 years. 45% were males, and the remaining females. 81% life in an urban area, and only 14% in a rural area. The educational level was categorized in 5 groups: without education, basic education, elementary school, high school, or college studies. 28% had basic education, and 19% college studies, and only 8% had no education at all. Their occupation was also categorized in five groups: home-keeping, student, unemployed, employed, and retired. 33% were employed, 29% retired, and 34% were home-keepers. Most of the patients (74%) are aware of their illness and perceive it as severe or very much severe. Most of these patients worry about their body image, weight, and ponderal changes, and they relate them with their feeding status. 74% find a relationship between their nutritional status and their physical activity, and 73% relate it with their mood. At least half of the patients perceive their mood as being low. Although 47% manifested having some difficulty for feeding, only 34% had received some information about their diet, 26% had consumed nutritional supplements, and 81% still consumed their diet without any change. The most common difficulties for feeding were decreased appetite (38%), early satiety (32%), and nausea (20%). The nutritional intervention most commonly required by the patients was general and specific nutritional education to alleviate the symptoms associated to oncologic therapies. Conclusions: Most of the patients are aware of the severity of their illness and care about their body image, weight, and ponderal changes, which they associate with their nutrition. Most of the patients find a close relationship between their nutritional status, their physical activity and their mood. More than half of the patients manifest having some difficulty feeding, but only one third of the population has received information about their diet some time. It is clearly shown that oncologic patients need different effective nutritional intervention measures contributing to improve their feeling of well being (AU)

Cirrhosis-like radiological pattern in patients with breast cancer

INTRODUCTION: Hepatic toxicity of breast cancer therapy is well known, usually consisting of elevation in the serum levels of hepatic enzymes or fatty infiltration of the liver. The chemotherapeutic agents most commonly linked to hepatotoxic effects are methotrexate, anthracyclines, taxanes and cyclophosphamide. There are few reports of patients with liver metastasis having radiological findings mimicking cirrhosis, both in the presence or the absence of prior systemic chemotherapy. Hepatotoxicity of antineoplastic drugs and cellular necrosis induced by response of liver metastases to chemotherapy may play a critical role in its physiopathology. MATERIALS AND METHODS: This article reports a series of ten women with breast cancer (nine with liver metastasis) treated with chemotherapy or hormonotherapy. RESULTS: They had low risk factors for hepatic disease, but developed a cirrhosis-like appearance in the computed tomography scan. The patient without liver metastasis is the second of this kind described in the literature. Relatively few reports have documented clinical sequelae of portal hypertension. In our series, three patients had oesophageal bleeding varices needing be hospitalised. To our knowledge, these are the first cases reported in the literature. CONCLUSIONS: This suggests that some manifestations of portal hypertension may develop in association with the cirrhosis- like pattern induced by breast cancer therapy (AU)

No disponible

[Nutritional risk evaluation and establishment of nutritional support in oncology patients according to the protocol of the Spanish Nutrition and Cancer Group]. / Evaluación del riesgo nutricional e instauración de soporte nutricional en pacientes oncológicos, según el protocolo del grupo Español de Nutrición y Cáncer.

INTRODUCTION: Cancer and its oncological treatment cause symptoms which increase the patients risk to suffer from malnutrition. This affects the patients health status negatively by increasing the number of complications, reducing the tolerance to the oncology treatment and a decrease of the patients quality of life. Motivated by this, a group of health professionals from several spanish regions met with the backing of the Sociedad Española de Nutrición Básica y Aplicada (SENBA) to address strategies to improve the quality of nutritional intervention in cancer patients. METHODS: This multidisciplinary group developed a protocol describing nutritional assessment and intervention in form of algorithms based on literature and personal experience. The patients are classified in a three step process: 1. type of their oncology treatment (curative or palliative); 2. nutritional risk of the antineoplastic therapy (low, medium or high risk) and 3. depending on the Subjective Global Assessment patient-generated (SGA-pg). The patients are classified as: A. patients with adequate nutritional state, B. patients with malnutrition or risk of malnutrition and C. patients suffering from severe malnutrition. During one year, the protocol has been used for 226 randomly chosen female and male patients older than 18 years. They were treated by the Medical and Radiotherapy Oncology outpatient clinic. RESULTS: More than a half of the patients were suffering from malnutrition (64%) increasing up to 81% for patients undergoing palliative treatment. Most of them were treated curatively (83%) and received oncology treatment with moderate or high nutritional risk (69%). 68% of patients were affected by some feeding difficulty. The mean percentage of weight loss has been 6.64% +/- 0.87 (min 0%, max 33%). Albumin values of 32% of the patients were between 3 and 3.5 g/dl and negatively correlated with feeding difficulties (p = 0.001). The body mass index (BMI) has not found to be a significant parameter for detecting malnutrition (only in 10% of the patients, the value was below 19.9 kg/m2). But a significant linear tendency when compared to feeding problems could be shown, such that in patients with less feeding problems a higher BMI has been found (p = 0.001). More than a half of the patients required nutritional counselling to control symptoms which made food intake difficult. One third of the patients needed oral nutritional supplementation. Following the nutritional intervention the weight of about 60% of the patients could be maintained and of one sixth it could be increased. CONCLUSION: The application of this protocol is useful, easy and could help detecting malnutrition in oncology patients. It provides the possibility to select those patients who can benefit from a specific nutritional intervention. If possible, the application of the protocol should be started immediatly after cancer is diagnosed. Nutritional support proves efficient for most of the patients.

[Self-perception of cancer patients on the relationship existing between their nutritional status, their feeding status, and their illness]. / Autopercepción de los pacientes con cáncer sobre la relación existente entre su estado nutricional, su alimentación y la enfermedad que padecen.

INTRODUCTION: Knowing the opinion of oncologic patients about the importance they give to their feeding, the difficulties they have with feeding, their body image, weight, and ponderal changes, the relationship between their feeding and their illness, the relationship between their physical activity and their mood and health is essential to look for nutritional therapeutic interventions leading to improvement of quality of life and, in general, the feeling of well being. Thus, it is paramount to know the patients' opinion of these issues. MATERIAL AND METHODS: We passed a questionnaire to 131 patients. The patients were recruited from the Day-Hospital of the Medical Oncology and Radiotherapeutic Oncology Departments, and from the Hospitalization Department of Medical Oncology. In the questionnaire, we asked in a simple manner about the importance the patients give to all these issues. This is a 20-item questionnaire, divided into six parts: 1. Vital statistics; 2) perception about the disease and its relationship with feeding; 3) Perception of the relationship between physical activity and mood with feeding; 4) Nutritional therapies prescribed to the patients and their perception on its effect on the disease progression; 5) Current difficulties with feeding; 6) Demand of nutritional care. RESULTS: The patients mean age was 57 +/- 13 years. 45% were males, and the remaining females. 81% life in an urban area, and only 14% in a rural area. The educational level was categorized in 5 groups: without education, basic education, elementary school, high school, or college studies. 28% had basic education, and 19% college studies, and only 8% had no education at all. Their occupation was also categorized in five groups: home-keeping, student, unemployed, employed, and retired. 33% were employed, 29% retired, and 34% were home-keepers. Most of the patients (74%) are aware of their illness and perceive it as severe or very much severe. Most of these patients worry about their body image, weight, and ponderal changes, and they relate them with their feeding status. 74% find a relationship between their nutritional status and their physical activity, and 73% relate it with their mood. At least half of the patients perceive their mood as being low. Although 47% manifested having some difficulty for feeding, only 34% had received some information about their diet, 26% had consumed nutritional supplements, and 81% still consumed their diet without any change. The most common difficulties for feeding were decreased appetite (38%), early satiety (32%), and nausea (20%). The nutritional intervention most commonly required by the patients was general and specific nutritional education to alleviate the symptoms associated to oncologic therapies. CONCLUSIONS: Most of the patients are aware of the severity of their illness and care about their body image, weight, and ponderal changes, which they associate with their nutrition. Most of the patients find a close relationship between their nutritional status, their physical activity and their mood. More than half of the patients manifest having some difficulty feeding, but only one third of the population has received information about their diet some time. It is clearly shown that oncologic patients need different effective nutritional intervention measures contributing to improve their feeling of well being.

Avances en el tratamiento sintomático del paciente oncológico

No disponible

Radioquimioterapia preoperatoria frente a postoperatoria en el carcinoma de recto estadios II-III: estudio comparativo no aleatorizado / Preoperative versus postoperative radiochemotherapy in stages II and III rectal carcinoma: a non-randomized comparative study

Propósito: comparar la eficacia, toxicidad y tasa de complicaciones quirúrgicas del tratamiento adyuvante frente al tratamiento neoadyuvante en el carcinoma de recto.• Material y métodos: 111 pacientes con carcinoma de recto estadios II-III recibieron tratamiento complementario con radioterapia (RT) y quimioterapia (QT). La QT consistió en leucovorin (500 mg/m2) intravenoso el primer día, seguido de lencovorin oral 15 mg/12 horas entre los días 2 y 14 del ciclo, y UFT 390 mg/m2/día entre los días 1 y 14 (350 mg/m2 durante la RT) . En 32 enfermos el tratamiento se realizó de forma neoadyuvante (grupo N), mientras que en los 79 restantes se administró tras la cirugía (grupo A).• Resultados: no hubo diferencias significativas en la supervivencia libre de enfermedad (72 por ciento en el grupo A y 69 por ciento en el grupo N) ni en la supervivencia global a los 3 años (91 por ciento en el grupo A y 95 por ciento en el grupo N). La tasa de complicaciones mayores tras la cirugía fue similar en ambos grupos. La tasa de diarrea grado 3-4 fue del 43 por ciento en los primeros 14 pacientes del grupo N (que recibieron UFT 350 mg/m2), mientras que en el grupo A fue del 18 por ciento (Fisher, p=0.07). En los restantes 18 pacientes del grupo N la dosis de UFT fue reducida a 300 mg/m2. La tasa de cirugía conservadora de esfínter en los tumores situados en los 10 cm últimos del recto fue superior en el grupo N (53 por ciento vs 38 por ciento, p=n.s.).• Conclusiones: el tratamiento neoadyuvante en el cáncer de recto no presenta diferencias significativas con el tratamiento adyuvante en cuanto a tasa de complicaciones quirúrgicas, tasa de recaídas y supervivencia, pero sí aumenta la toxicidad gastrointestinal. (AU)

Prevalencia de la desnutrición en oncología / No disponible

No disponible

[Superior vena cava syndrome: presentation of six cases]. / Síndrome de vena cava superior: presentación de seis casos.

Superior vena cava syndrome is a devastating complication of obstructive lesions compromising the superior vena cava an its branches. Most cases today are caused by malignant tumors. The most frequent are lung carcinoma. The clinical presentation is dyspnea, vuvular enlargement, collateral circulation. Imaging techniques and histological confirmation are used for diagnosis. Early diagnosis and treatment is needed. The following report deals with six patients with superior vena cava syndrome. All entered our hospital through Emergency Department. The description of the principal symptoms and sings, the early diagnosis and the treatment.

Síndrome de vena cava superior: presentación de seis casos / Superior vena cava syndrome: presentation of six cases

El síndrome de vena cava superior (SVCS), es el conjunto de síntomas y signos derivados de la obstrucción parcial o completa de la vena cava superior. Su diagnóstico precoz, es fundamental para un tratamiento eficaz. Las enfermedades malignas son la causa principal, siendo la más frecuente el cáncer de pulmón. La clínica se caracteriza por la disnea y la triada clásica de edema en esclavina, cianosis facial y circulación colateral tóraco-braquial. En el diagnóstico se utilizan técnicas de imagen, siendo preciso para su confirmación, un diagnóstico histológico. El tratamiento ha de ser lo más precoz posible.En el presente trabajo se describen los casos de seis pacientes con SVCS, que ingresaron desde el Servicio de Urgencias de nuestro hospital.Se repasan los principales síntomas y signos, los métodos diagnósticos y el tratamiento empleado, haciendo especial mención a la precocidad en su detención. (AU)

Reinserción laboral del paciente neoplásico / Reintegration to work of the patients with cancer

Propósito: Analizar la reinserción laboral en los pacientes diagnosticados de cáncer. Material y métodos: Se ha realizado una encuesta a 96 pacientes neoplásicos que desempeñaban un empleo remunerado en el momento del diagnóstico. Resultados: Durante el tratamiento, 8 pacientes (9 por ciento) permanecieron laboralmente activos y 79 (82 por ciento) tuvieron ILT. Tras finalizar éste, 67 enfermos (70 por ciento) desarrollaban alguna actividad laboral y 11 (11 por ciento) continuaban con ILT. Quedaron con secuelas 48 personas (50 por ciento), de las cuales 24 (50 por ciento) pudieron volver al trabajo, frente a 43 (90 por ciento) de las que no presentaron secuelas (p<0,01). Conclusiones: El 70 por ciento de los pacientes que sobreviven al tratamiento de primera línea de una neoplasia logran reinsertarse en el ámbito laboral. Es necesario desarrollar esquemas terapéuticos que, manteniendo la eficacia, reluzcan al mínimo las secuelas (AU)

Fascitis-paniculitis como manifestación paraneoplásica de un linfoma no Hodgkin paracortical nodular T / Fascitis-panniculitis as a paraneoplastic manifestation of a paracortical nodular T cell no-Hodgkin's lymphoma

No disponible

Carboplatino -Tegafur- Leucovorin en el tratamiento del cáncer de mama avanzado / Carboplatin-Tegafur-Leucovorin in the treatment of advanced breast cancer

Propósito: Valorar la eficacia y seguridad del esquema Carboplatino -Tegafur- Leucovorín como tratamiento quimioterápico en el cáncer de mama avanzado. Material y métodos: Entre 1992-97 fueron tratadas con este régimen 19 pacientes (entre 34 y 76 años) con metástasis en distintas localizaciones y que habían recibido ya una o más líneas previas de quimioterapia. Resultados: Se administraron entre 1 y 12 ciclos por paciente. Las principal toxicidad fue: neutropenio, anemia y trombopenia y naúseas y vómitos. No ocurrieron muertes tóxicas. Hubo 1 remisión completa y 4 remisiones parciales. ConcIusiones: El régimen Carboplatino -Tegafur- Leucovorín es moderadamente eficaz como tratamiento de segunda o tercera línea en el cáncer de mama avanzado. La toxicidad, fundamentalmente hematológica, no es demasiado elevada por lo que puede ser una opción más de tratamiento en esos casos (AU)